Skip to content
10-Q

Quarterly Report

Unicycive Therapeutics, Inc. UNCY

0001213900-26-054708

← back to feed
Filed
May 12, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 12, 2026 26.7M sh
Shares Diluted Q1 2026 · Mar 31, 2026 23.91M sh
Shares Diluted restated Q1 2026 · Mar 31, 2025 12.38M sh
Capex Q1 2026 · Mar 31, 2026 $8K
Capex Q1 2026 · Mar 31, 2025 $16K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$6.24M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$8.9M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $37.37M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $29.2M
Stockholders Equity Q1 2026 · Mar 31, 2026 $37.7M
Stockholders Equity Q1 2026 · Dec 31, 2025 $30.2M
Stockholders Equity Q1 2026 · Mar 31, 2025 $11.27M
Stockholders Equity Q1 2026 · Dec 31, 2024 $7.43M
Current Liabilities Q1 2026 · Mar 31, 2026 $26.49M
Current Liabilities Q1 2026 · Dec 31, 2025 $18.94M
Total Liabilities Q1 2026 · Mar 31, 2026 $26.7M
Total Liabilities Q1 2026 · Dec 31, 2025 $18.94M
Current Assets Q1 2026 · Mar 31, 2026 $63.55M
Current Assets Q1 2026 · Dec 31, 2025 $48.96M
Total Assets Q1 2026 · Mar 31, 2026 $64.41M
Total Assets Q1 2026 · Dec 31, 2025 $49.14M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.54
Eps Diluted restated Q1 2026 · Mar 31, 2025 −$0.50
Eps Basic Q1 2026 · Mar 31, 2026 −$0.54
Eps Basic Q1 2026 · Mar 31, 2025 $0.04
Rd Expense Q1 2026 · Mar 31, 2026 $1.61M
Rd Expense Q1 2026 · Mar 31, 2025 $2.17M
Net Income Q1 2026 · Mar 31, 2026 −$12.82M
Net Income Q1 2026 · Mar 31, 2025 $570K
Operating Income Q1 2026 · Mar 31, 2026 −$8.44M
Operating Income Q1 2026 · Mar 31, 2025 −$7.99M